Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ELAN 
Elanco Animal Health (ELAN)
Today’s top pick
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: ELAN (5-star) is a STRONG-BUY. BUY since 5 days. Simulated Profits (1.82%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $25
1 Year Target Price $25
| 6 | Strong Buy |
| 1 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 91.36% | Avg. Invested days 60 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.55B USD | Price to earnings Ratio 332 | 1Y Target Price 25 |
Price to earnings Ratio 332 | 1Y Target Price 25 | ||
Volume (30-day avg) 15 | Beta 1.87 | 52 Weeks Range 8.02 - 23.89 | Updated Date 01/8/2026 |
52 Weeks Range 8.02 - 23.89 | Updated Date 01/8/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.78% | Operating Margin (TTM) 2.38% |
Management Effectiveness
Return on Assets (TTM) 1.15% | Return on Equity (TTM) 0.54% |
Valuation
Trailing PE 332 | Forward PE 21.74 | Enterprise Value 14867361723 | Price to Sales(TTM) 2.52 |
Enterprise Value 14867361723 | Price to Sales(TTM) 2.52 | ||
Enterprise Value to Revenue 3.24 | Enterprise Value to EBITDA 17.7 | Shares Outstanding 496863473 | Shares Floating 492878628 |
Shares Outstanding 496863473 | Shares Floating 492878628 | ||
Percent Insiders 1.07 | Percent Institutions 116.42 |
Upturn AI SWOT
Elanco Animal Health
Company Overview
History and Background
Elanco Animal Health was founded in 1954 as a division of Eli Lilly and Company, focusing on animal health products. In 2018, Elanco was spun off from Eli Lilly as an independent, publicly traded company. Significant milestones include the acquisition of Novartis Animal Health in 2015 and Bayer Animal Health in 2019, significantly expanding its portfolio and market reach. Elanco has evolved into a global leader in the animal health industry, committed to innovation and sustainability.
Core Business Areas
- Companion Animal: This segment focuses on products for pets, including pharmaceuticals for parasiticides, pain management, and other therapeutic areas. Key offerings include flea and tick control, heartworm prevention, and treatments for osteoarthritis.
- Farm Animal: This segment addresses the health and well-being of food-producing animals such as cattle, poultry, swine, and aquaculture. Products include vaccines, antibiotics, nutritional health solutions, and parasiticides aimed at improving animal productivity and preventing disease.
Leadership and Structure
Elanco Animal Health is led by a dedicated executive leadership team, with a Board of Directors overseeing corporate governance. The company operates globally, organized by business segments and geographical regions to effectively serve its diverse customer base.
Top Products and Market Share
Key Offerings
- Credelio/Elanco's portfolio of parasiticides (e.g., Credelio, Comfortis, Interceptor Plus, Trifexis): These products are highly effective treatments and preventatives for fleas, ticks, and heartworm in companion animals. Elanco holds a significant share in the parasiticides market, facing competition from companies like Zoetis, Boehringer Ingelheim, and Merck Animal Health. Specific market share figures for individual products are proprietary but collectively contribute significantly to Elanco's revenue.
- Galliprant: A non-steroidal anti-inflammatory drug (NSAID) for osteoarthritis pain in dogs. It offers a differentiated approach to pain management in companion animals and competes with other NSAIDs and pain management therapies from competitors like Zoetis and Boehringer Ingelheim.
- Virbac's Portfolio: While Virbac is a competitor, Elanco also has a diverse portfolio addressing various farm animal health needs, including vaccines and feed additives that contribute to disease prevention and growth promotion in livestock. Competitors in this space include Zoetis, Boehringer Ingelheim, and Merck Animal Health.
Market Dynamics
Industry Overview
The global animal health market is characterized by increasing pet ownership, rising demand for safe and sustainably produced animal protein, and a growing awareness of zoonotic diseases. The industry is driven by innovation in pharmaceuticals, vaccines, diagnostics, and digital solutions. Key trends include a shift towards biologics, personalized medicine, and preventative care.
Positioning
Elanco Animal Health is a leading global player in the animal health industry, distinguished by its broad portfolio serving both companion and farm animals. Its competitive advantages lie in its strong brand recognition, extensive distribution network, commitment to R&D, and strategic acquisitions that enhance its market presence and product offerings.
Total Addressable Market (TAM)
The global animal health market is substantial and growing, with estimates for its total addressable market often exceeding USD 60 billion and projected to grow at a CAGR of 5-7% over the next several years. Elanco is well-positioned within this TAM, with a significant presence in key therapeutic areas and animal segments, though it competes with other major animal health companies for market share.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio serving both companion and farm animals.
- Strong global presence and distribution network.
- Significant investment in research and development.
- Reputation for quality and innovation.
- Successful integration of acquired businesses (e.g., Bayer Animal Health).
Weaknesses
- Reliance on a few key products for a significant portion of revenue.
- Potential challenges in fully integrating and leveraging acquired technologies.
- Regulatory hurdles and patent cliffs for certain products.
- Competition from larger, more diversified pharmaceutical companies.
Opportunities
- Growing demand for pet care and wellness products.
- Increasing focus on food security and sustainable protein production.
- Expansion into emerging markets with growing animal populations.
- Leveraging digital technologies for animal health management.
- Development of novel therapeutics and preventative solutions.
Threats
- Intensifying competition and pricing pressures.
- Stringent regulatory environments and approval processes.
- Potential for disease outbreaks affecting livestock or companion animals.
- Economic downturns impacting consumer spending on pet care.
- Generic competition for established products.
Competitors and Market Share
Key Competitors
- Zoetis Inc. (ZTS)
- Merck & Co., Inc. (MRK)
- Boehringer Ingelheim Animal Health (Private)
- IDEXX Laboratories, Inc. (IDXX)
Competitive Landscape
Elanco competes in a consolidated animal health market. Its advantages include a broad product portfolio and strong brand equity. However, Zoetis is a dominant player with a strong presence in companion animal health, while Merck and Boehringer Ingelheim also possess extensive global reach and R&D capabilities. IDEXX leads in veterinary diagnostics. Elanco's strategy involves leveraging its scale and innovation to maintain and grow its market share.
Major Acquisitions
Bayer Animal Health
- Year: 2019
- Acquisition Price (USD millions): 7300
- Strategic Rationale: This landmark acquisition significantly expanded Elanco's product portfolio, particularly in parasiticides and vaccines, and strengthened its global market position, creating a more formidable competitor in the animal health industry.
Aratana Therapeutics
- Year: 2019
- Acquisition Price (USD millions): 450
- Strategic Rationale: This acquisition bolstered Elanco's portfolio of innovative therapeutics for companion animals, particularly in areas like pain management and oncology, enhancing its offerings for veterinary clinics.
Growth Trajectory and Initiatives
Historical Growth: Elanco has demonstrated a growth trajectory driven by organic sales growth and strategic acquisitions. The integration of Bayer Animal Health in 2019 significantly boosted its scale and market position, enabling it to compete more effectively. Organic growth is supported by innovation and market expansion.
Future Projections: Analyst projections for Elanco typically anticipate continued revenue growth, supported by the expanding animal health market, new product introductions, and penetration in key therapeutic areas. Focus areas include companion animal parasiticides, specialty therapeutics, and farm animal health solutions. Growth is also expected from leveraging its expanded global reach.
Recent Initiatives: Recent initiatives have focused on optimizing its product portfolio, investing in R&D for pipeline development, and enhancing operational efficiencies. Elanco has also been active in pursuing strategic partnerships and collaborations to drive innovation and market access.
Summary
Elanco Animal Health is a well-established leader in the global animal health sector, boasting a comprehensive product portfolio for both companion and farm animals. Its strategic acquisitions, particularly that of Bayer Animal Health, have significantly enhanced its market presence and diversification. The company benefits from strong R&D capabilities and a growing demand for animal health solutions. However, Elanco faces intense competition from major players and must continuously innovate and manage regulatory challenges to sustain its growth trajectory and capitalize on opportunities in emerging markets and advanced animal care.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Elanco Animal Health Investor Relations
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Market Research Reports (e.g., Grand View Research, Mordor Intelligence)
- Company SEC Filings (10-K, 10-Q)
Disclaimers:
This JSON output is a structured overview of Elanco Animal Health based on publicly available information and general industry knowledge. Financial data and market share percentages are estimates and may vary. This information is for informational purposes only and should not be considered financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elanco Animal Health
Exchange NYSE | Headquaters Greenfield, IN, United States | ||
IPO Launch date 2018-09-20 | President, CEO & Director Mr. Jeffrey N. Simmons | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 9000 | Website https://www.elanco.com |
Full time employees 9000 | Website https://www.elanco.com | ||
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.